EGFR and colorectal carcinoma: This molecular understanding has been translated into the first few molecularly targeted chemotherapeutic agents approved by the US Food and Drug Administration (FDA) for use in CRC, first the monoclonal antibodies cetuximab (anti-EGFR) and bevacizumab (anti-VEGF) in 2004 followed by panitumumab (anti-EGFR) in 20063.